Search results for "OUTCOME"

showing 10 items of 5148 documents

Childhood cancer:Survival, treatment modalities, late effects and improvements over time

2021

Since the 1960s, paediatric oncologists have gradually become better organised in large study groups and participation in clinical trials is today considered as the standard of care, with most children with cancer in Europe and North America being enrolled on available treatment protocols. Chemotherapy is nowadays the main element of therapy, but irradiation is still required for some patients. With the advent of multimodality therapy and supportive care, five-year cancer survival exceeds 80 % in most European and North American countries today. The substantial improvements in survival led to a constantly growing population of childhood cancer survivors. Concerns regarding the risk of late …

Cancer Researchmedicine.medical_specialtyTime FactorsSurvivalEpidemiologyPopulationMultimodality TherapySurvivorshipSocial and socioeconomic conditions03 medical and health sciencesSomatic late effects0302 clinical medicineQuality of life (healthcare)NeoplasmsSurvivorship curvemedicineHumans030212 general & internal medicineChild610 Medicine & healthIntensive care medicineeducationSocioeconomic statusClinical Trials as Topiceducation.field_of_studybusiness.industryCancerTemporal changesmedicine.diseaseCombined Modality TherapySurvival AnalysisMental healthSurvivor cohortsEuropeClinical trialTreatment OutcomeOncology030220 oncology & carcinogenesisCancer treatmentNorth AmericaMental late effectsbusinessChildhood cancer360 Social problems & social services
researchProduct

Prognostic assessment and treatment of primary gastric lymphomas: how endoscopic ultrasonography can help in tailoring patient management.

2013

Endoscopic ultrasonography (EUS) has recently gained a pivotal role in the management of gastric lymphomas, especially in the diagnostic workup. Its accuracy and reliability have overcome those of other imaging techniques, such that it represents an invaluable tool for the management of gastric lymphomas. Although this technique is operator dependent, its application in large series has proved its reliability. Thus, it has generally been considered a useful tool for providing information crucial in deciding the treatment program, especially for mucosa-associated lymphoid tissue (MALT) lymphomas, for which EUS can provide an accurate evaluation of disease extension and treatment response pro…

Cancer Researchmedicine.medical_specialtyTreatment responseDecision MakingEndoscopic ultrasonographyDiseaseGastroenterologyEndosonographyStomach NeoplasmsSubmucosaInternal medicinemedicineHumansNeoplasm Stagingbiologybusiness.industryGastric lymphomaStomachLymphoma Non-HodgkinDisease ManagementHematologyHelicobacter pylorimedicine.diseasebiology.organism_classificationPrognosisdigestive system diseasesPatient managementmedicine.anatomical_structureTreatment OutcomeOncologyRadiologybusinessClinical lymphoma, myelomaleukemia
researchProduct

Primary optic nerve sheath meningioma

2007

BACKGROUND. Radiotherapy (RT) has occasionally been practiced in the treatment of optic nerve sheath meningioma (ONSM). Recently, stereotactic fractionated RT (SFRT) has been introduced as a tool with better precision for RT delivery. A comprehensive review was undertaken to provide more insight into this matter. METHODS. A literature search was performed to identify reports dealing with both clinical aspects (diagnosis) and treatment in ONSM, focusing on RT in primary (p)ONSM. In particular, major emphasis was placed on the role of SFRT in pONSM. RESULTS. SFRT was capable of achieving excellent local tumor control, with improved/stable functional capacity in ≥80%, accompanied with very low…

Cancer Researchmedicine.medical_specialtyVisual acuitymedicine.medical_treatmentNerve Sheath NeoplasmsStereotaxic TechniquesMeningiomaMeningeal NeoplasmsmedicineHumansbusiness.industryOptic Nerve NeoplasmsDose fractionationCancermedicine.diseaseOptic nerve sheath meningiomaSurgeryRadiation therapyTreatment OutcomeOncologyStereotaxic techniqueOptic nerveDose Fractionation RadiationRadiotherapy Conformalmedicine.symptomMeningiomabusinessCancer
researchProduct

2020

The disease and treatment of patients with head and neck cancer can lead to multiple late and long-term sequelae. Especially pain, psychosocial problems, and voice issues can have a high impact on patients’ health-related quality of life. The aim was to show the feasibility of implementing an electronic Patient-Reported Outcome Measure (PROM) in patients with head and neck cancer (HNC). Driven by our department’s intention to assess Patient-Reported Outcomes (PRO) based on the International Classification of Functioning during tumor aftercare, the program “OncoFunction” has been implemented and continuously refined in everyday practice. The new version of “OncoFunction” was evaluated by 20 …

Cancer Researchmedicine.medical_specialtybusiness.industryHead and neck cancerDiseasePrommedicine.disease03 medical and health sciences0302 clinical medicineOncologyQuality of lifeInternational Classification of Functioning Disability and Health030220 oncology & carcinogenesismedicinePhysical therapyIn patientPatient-reported outcome030223 otorhinolaryngologybusinessPsychosocialFrontiers in Oncology
researchProduct

Cancer and Pregnancy: A Comprehensive Review

2021

Simple Summary The co-occurrence of cancer and pregnancy is fortunately a rare event. It is a challenging situation for all involved parties, as the risks and benefits of oncological treatments should be balanced for both the mother and the offspring. This work offers guidance to clinicians regarding the choice of diagnostic and therapeutic procedures, as well as regarding the management of the pregnancy. Abstract Cancer diagnosis and treatment in pregnant women is a challenging situation. A multidisciplinary network of specialists is required to guide both, the expecting mother and the unborn child through the diagnostic workup and the cytotoxic therapy, by balancing the respective risks a…

Cancer Researchmedicine.medical_specialtydiagnostic proceduresfetal outcomeReviewtherapeutic procedures03 medical and health sciences0302 clinical medicineUnborn childMultidisciplinary approachmedicinecancer030212 general & internal medicineRisks and benefitsStage (cooking)Intensive care medicineCytotoxic TherapyRC254-282PregnancyNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancermedicine.diseaseOncology030220 oncology & carcinogenesisFetal outcomepregnancyCancers
researchProduct

Risk factors for recurrence after robot-assisted radical hysterectomy for early-stage cervical cancer: a multicenter retrospective study

2020

This retrospective analysis aimed to assess the risk factors for recurrence in patients diagnosed with early-stage cervical cancer (&le

Cancer Researchmedicine.medical_specialtyrecurrenceSentinel lymph nodelcsh:RC254-282Article03 medical and health sciences0302 clinical medicineBiopsyrobotic surgerymedicineRadical HysterectomyStage (cooking)CàncerCancerCervical cancer030219 obstetrics & reproductive medicinemedicine.diagnostic_testoncological outcomeCirurgiabusiness.industryHazard ratioRetrospective cohort studymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenshumanitiesbody regionsOncologyEstudi de casos030220 oncology & carcinogenesisradical hysterectomyearly-stage cervical cancerAdenocarcinomaSurgeryRadiologyCase studiesbusiness
researchProduct

Population-based study of breast cancer in older women: prognostic factors of relative survival and predictors of treatment

2012

Abstract Background A large proportion of women with breast cancer (BC) are elderly. However, there is a lack of information regarding BC prognostic factors and care in this population. The aims of this study were to assess the prognostic factors of relative survival (RS) among women with BC aged ≥ 75 years old and to identify the predictive factors of treatments administered to this population. Methods A population-based study was performed using data from the Cote d’Or breast and gynaecological cancer registry. Women aged 75 years and older with primary invasive BC and resident in Cote d’Or at the time of diagnosis made between January 1998 and December 2008 were retrospectively selected.…

Cancer Researchmedicine.medical_treatmentComorbidityBreast cancerBreast-conserving surgeryRegistriesMastectomyAged 80 and overeducation.field_of_studyPredictors of treatmentRelative survivalPrognosislcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCombined Modality TherapyTreatment OutcomeOncologyPopulation SurveillanceHypertensionFemaleFranceMastectomyResearch Articlemedicine.medical_specialtyPopulationBreast NeoplasmsPrognostic factorsRelative survivallcsh:RC254-282Breast cancerDrug TherapyInternal medicineDiabetes MellitusmedicineAdjuvant therapyGeneticsHumansObesityElderly womeneducationSurvival analysisAgedNeoplasm StagingRetrospective StudiesGynecologyRadiotherapybusiness.industrymedicine.diseaseSurvival AnalysisLogistic ModelsMultivariate AnalysisHormone therapybusinessFollow-Up StudiesBMC Cancer
researchProduct

Droloxifene-Induced Spikes of Tumor Markers Predict Benefit of Therapy

1991

In the clinical monitoring of cancer, tumor marker proteins may reflect the status of the disease. In cases with radio- and chemotherapy, spikes of tumor markers were found shortly after starting the therapy. These spikes were interpreted as a sign of tumor lysis. Recently during therapy of breast cancer with the new antiestrogen droloxifene, spikes of CA 125 and CA 15-3 were also found in about one-third of patients responding to therapy. The peaks of these initial increases were recorded between 14 and 60 days after the onset of treatment, with maximum concentrations up to 1,890% of the initial value. Marker concentrations decreased thereafter, to new baselines at or below the initial val…

Cancer Researchmedicine.medical_treatmentRadioimmunoassayAntineoplastic AgentsBreast NeoplasmsBreast cancerPredictive Value of TestsmedicineHumansAntigens Tumor-Associated CarbohydrateAgedTumor markerChemotherapybusiness.industryEstrogen AntagonistsCancerRadioimmunoassayMiddle Agedmedicine.diseaseAntiestrogenTamoxifenTreatment OutcomeOncologyPredictive value of testsCancer researchDrug EvaluationFemalebusinessTamoxifenmedicine.drugAmerican Journal of Clinical Oncology
researchProduct

Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study

2011

Objectives: To provide a global, up-to-date picture of the prevalence, treatment, and outcomes of Candida bloodstream infections in intensive care unit patients and compare Candida with bacterial bloodstream infection. Design: A retrospective analysis of the Extended Prevalence of Infection in the ICU Study (EPIC II). Demographic, physiological, infection-related and therapeutic data were collected. Patients were grouped as having Candida, Gram-positive, Gram-negative, and combined Candida/bacterial bloodstream infection. Outcome data were assessed at intensive care unit and hospital discharge. Setting: EPIC II included 1265 intensive care units in 76 countries. Patients: Patients in partic…

Candida albicanMaleAntifungal AgentsIron metabolism Pathogenesis and modulation of inflammation [IGMD 7]Settore MED/41 - AnestesiologiaCritical Care and Intensive Care Medicinelaw.inventionEchinocandinschemistry.chemical_compound0302 clinical medicineRetrospective StudieCaspofunginlawCandida albicansPrevalenceAntifungal Agent030212 general & internal medicineCandida albicansFluconazoleMESH: SepsisFungemiaintensive careMedicine(all)MESH: AgedCross Infection0303 health scienceseducation.field_of_studyMESH: Middle AgedfungemiabiologyCandidiasisMiddle AgedIntensive care unitMESH: Candidiasisbacteremia; epidemiology; fungemia; intensive care; outcome assessment (health care); Aged; Antifungal Agents; Candida albicans; Candidiasis; Cross Infection; Echinocandins; Female; Fluconazole; Humans; Intensive Care Units; Lipopeptides; Male; Middle Aged; Prevalence; Retrospective Studies; Sepsis; Critical Care and Intensive Care Medicine3. Good healthIntensive Care Unitsbacteremia epidemiology fungemia intensive care outcome assessment (health care)CandidiasiMESH: FluconazoleepidemiologyFemaleHumanmedicine.drugmedicine.medical_specialtySepsiIntensive Care UnitPopulationLipopeptides03 medical and health sciencesSepsisIntensive caremedicineHumansEchinocandinbacteremiaIntensive care medicineeducationMESH: PrevalenceAgedRetrospective Studiesoutcome assessment (health care)MESH: Humans030306 microbiologybusiness.industryMESH: Candida albicansMESH: EchinocandinsMESH: Cross InfectionMESH: Retrospective Studies[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Antifungal Agentsmedicine.diseasebiology.organism_classificationMESH: MalechemistryBacteremiaMESH: Intensive Care UnitsCaspofunginbusinessMESH: FemaleFluconazole
researchProduct

Pharmacogenomics: a tool to prevent and cure coronary heart disease.

2007

Inflammation and genetics play an important role in the pathogenesis of coronary heart disease (CHD). This is supported by epidemiological studies which have thoroughly investigated the association between CHD and gene polymorphisms of the inflammatory molecules. Moreover, efforts to find elective therapy have not been rewarding and, despite the increasing appreciation of the role of genetics in CHD and myocardial infarction (MI) pathogenesis, pharmacogenomic approaches to uncover drug target have not been extensively explored. A critical search of published literature has suggested few inflammatory genes directly involved in the risk to develop CHD and MI. The selected genes are, the pro- …

Candidate genepharmacogenomicLipoxygenaseLipopolysaccharide ReceptorsMyocardial InfarctionCoronary DiseaseDiseaseBioinformaticsRisk AssessmentPathogenesisRisk FactorsDrug DiscoverymedicinecytokineHumansGenetic Predisposition to DiseaseMyocardial infarctionTLR4PharmacologyInflammationPolymorphism Geneticbusiness.industryPatient SelectionCase-control studyCOXLOXmedicine.diseaseAtherosclerosisToll-Like Receptor 4Treatment OutcomePharmacogeneticsProstaglandin-Endoperoxide SynthasesPharmacogenomicsCase-Control StudiesImmunologyCytokinesReceptors ChemokineChemokinesbusinessRisk assessmentCD14CCR5PharmacogeneticsCurrent pharmaceutical design
researchProduct